Tanner Pharma Partners with Biodexa to Promote eRapa
Tanner Pharma Group and Biodexa Pharmaceuticals have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis, FAP, through an Early Access / Named Patient Program. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa in countries where it is not currently available, allowing clinicians treating FAP patients to prescribe this investigational therapy outside of a clinical trial for the first time.
